Breast augmentation with implants has short- and long-term risks. Whether the expected benefit outweighs those risks for you can only be assessed after examination, counselling and shared decision-making.
General surgical risks such as bleeding, infection, thrombosis and embolism exist with every operation. We actively reduce them: through meticulous haemostasis, a single-shot antibiotic during surgery, the shortest possible operating times, early mobilisation on the day of surgery and an anti-thrombosis injection during the short inpatient stay. Even so, they cannot be reduced to zero.
Implant-specific risks include capsular contracture, displacement or shape change, pain, altered sensation, rippling, seroma, implant rupture and further operations. Silicone-gel implants can rupture without obvious symptoms; ultrasound or MRI may be advised depending on the implant, symptoms and individual risk. Breast implants are not lifetime devices and may need to be removed or replaced later.
The rare lymphoma BIA-ALCL is associated with breast implants and is currently reported more often with textured than with smooth surfaces. Rare squamous-cell carcinomas and other lymphomas have also been reported in the implant capsule. Late one-sided swelling, fluid, a mass, shape change or persistent pain needs prompt assessment.
Autoimmune phenomena such as Sjögren’s syndrome, chronic fatigue or rheumatoid arthritis have also been studied in connection with breast implants (ASIA syndrome, “breast implant illness”). To date there is no sufficient evidence of a clear causal link – further research is needed. We address these topics openly in the consultation.